The FDA on November 14, 2014 approved AVASTINĀ® in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. AVASTINĀ® is a product of Genentech, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
